Compare
Westin Acquisition Corp vs LifeMD, Inc. vs Cardiff Lexington Corp vs Starling Oncology, Inc.
| Latest fiscal year | Westin Acquisition Corp WSTN | LifeMD, Inc. LFMD | Cardiff Lexington Corp CDIX | Starling Oncology, Inc. STLN |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $194.06M | $11.54M | $502.73M |
| Revenue growth (YoY) | n/a | +25.3% | +39.5% | +27.8% |
| Gross margin | n/a | 85.7% | 62.5% | n/a |
| Operating margin | n/a | -4.0% | 9.5% | -7.2% |
| Net margin | n/a | 7.4% | -47.7% | -12.1% |
| Net income | $890.4K | $14.35M | -$5.51M | -$60.61M |
| EPS (Diluted) | n/a | $0.25 | n/a | -$0.54 |
| Operating cash flow | -$331.0K | $8.28M | -$2.85M | -$24.59M |
| Free cash flow | n/a | $6.41M | n/a | -$27.79M |
| Cash & equivalents | n/a | n/a | n/a | n/a |
| Total assets | $59.20M | $70.41M | $29.09M | $164.66M |
| Total liabilities | $2.90M | $47.25M | $26.01M | $180.38M |
| Shareholders' equity | $1.86M | $23.16M | -$2.47M | -$15.72M |
| Return on year-end equity | 47.9% | 62.0% | n/a | n/a |
| Shares outstanding | n/a | 46.66M | 13.70M | 98.86M |
Revenue, most recent five fiscal years
| Fiscal year | Westin Acquisition Corp | LifeMD, Inc. | Cardiff Lexington Corp | Starling Oncology, Inc. |
|---|---|---|---|---|
| Latest | n/a | $194.06M Ended 2025-12-31 | $11.54M Ended 2025-12-31 | $502.73M Ended 2025-12-31 |
| 1 year earlier | n/a | $154.82M Ended 2024-12-31 | $8.27M Ended 2024-12-31 | $393.41M Ended 2024-12-31 |
| 2 years earlier | n/a | $152.55M Ended 2023-12-31 | $11.85M Ended 2023-12-31 | $324.24M Ended 2023-12-31 |
| 3 years earlier | n/a | $119.03M Ended 2022-12-31 | $10.69M Ended 2022-12-31 | $252.48M Ended 2022-12-31 |
| 4 years earlier | n/a | $92.88M Ended 2021-12-31 | $9.88M Ended 2021-12-31 | $203.00M Ended 2021-12-31 |